Targeting H3.3 Mutations in Pediatric HGG
Brendan Price, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Pediatric high-grade gliomas (pHGG) have few treatment options and most children diagnosed only survive for 1-2 years. Identifying new treatments is therefore of the highest priority. Work in the lab is focused on understanding how these brain tumors arise, with the …